Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Kaleido Biosciences Inc (KLDO)

Kaleido Biosciences Inc (KLDO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 6,393
  • Shares Outstanding, K 42,623
  • Annual Sales, $ 1,104 K
  • Annual Income, $ -90,288 K
  • 60-Month Beta -0.06
  • Price/Sales 11.00
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade KLDO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.10
  • Most Recent Earnings $-0.54 on 11/01/21
  • Latest Earnings Date 05/03/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/22
See More
  • Average Estimate -0.51
  • Number of Estimates 1
  • High Estimate -0.51
  • Low Estimate -0.51
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +12.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0001 unch
on 04/15/24
0.0001 unch
on 04/15/24
unch (unch)
since 03/14/24
3-Month
0.0001 unch
on 04/15/24
0.0001 unch
on 04/15/24
unch (unch)
since 12/20/23
52-Week
0.0001 unch
on 04/15/24
0.0300 -99.67%
on 09/15/23
-0.0001 (-50.00%)
since 04/14/23

Most Recent Stories

More News
Exelixis (EXEL) Initiates Early Stage Study of Lymphoma

Exelixis (EXEL) commences the dose-escalation stage of the phase I study of XL114 in patients with non-Hodgkin's lymphoma.

BMY : 48.51 (+0.48%)
EXEL : 22.70 (-0.48%)
VYGR : 8.24 (-2.25%)
KLDO : 0.0001 (unch)
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

CRXT and PTGX are leading our lists this morning

MILE : 1.0500 (+7.67%)
CRXT : 0.0475 (-31.16%)
LMND : 16.35 (-2.56%)
DLPN : 1.2600 (+1.25%)
KLDO : 0.0001 (unch)
Why Is Creatd (CRTD) Stock Up Today?

Urban Outfitters is teaming up with Dune

CRTD : 2.0400 (-0.10%)
HPK : 15.14 (-0.92%)
SRRA : 54.99 (+0.04%)
URBN : 38.21 (-1.44%)
KLDO : 0.0001 (unch)
Dear KLDO Stock Fans, Mark Your Calendars for April 28

Retail traders are pumping KLDO today

HPK : 15.14 (-0.92%)
SRRA : 54.99 (+0.04%)
UBER : 73.40 (-2.50%)
KLDO : 0.0001 (unch)
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

GNCA and GWGH are leading our pre-market stock movers today

GNCA : 0.0001 (unch)
GFAI : 2.69 (-16.98%)
SAIL : 65.24 (+0.25%)
VERU : 1.5300 (+0.66%)
KLDO : 0.0001 (unch)
Vertex's (VRTX) Pain Candidate Meets Goal in Two Studies

Vertex's (VRTX) two phase II proof-of-concept studies evaluating VX-548 for acute pain following abdominoplasty surgery or bunionectomy surgery meets the primary endpoint.

VRTX : 397.36 (+0.20%)
ATHX : 0.0135 (-33.50%)
CRSP : 58.72 (-3.21%)
KLDO : 0.0001 (unch)
Novartis (NVS) Beovu Gets Label Expansion for DME in EU

Novartis (NVS) ophthalmology drug Beovus label gets expanded in EU for diabetic macular edema.

REGN : 898.56 (-0.68%)
NVS : 94.41 (+0.95%)
VRTX : 397.36 (+0.20%)
KLDO : 0.0001 (unch)
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 14.29% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

DARE : 0.4801 (+2.28%)
KLDO : 0.0001 (unch)
Roche (RHHBY) Late-Stage Study for ES-SCLC Fails to Meet Goal

Roche (RHHBY) phase III SKYSCRAPER-02 study assessing tiragolumab plus Tecentriq and chemotherapy as a first-line treatment for extensive-stage small cell lung cancer did not meet co-primary endpoint of...

RHHBY : 30.5800 (-0.03%)
VRTX : 397.36 (+0.20%)
VYGR : 8.24 (-2.25%)
KLDO : 0.0001 (unch)
Bristol Myers (BMY) Application for Opdivo With Chemo Validated

Bristol Myers (BMY) type II variation application for Opdivo in combination with chemotherapy for the neoadjuvant treatment of patients with non-small cell lung cancer gets EMA validation.

BMY : 48.51 (+0.48%)
MRK : 126.19 (+0.36%)
VRTX : 397.36 (+0.20%)
KLDO : 0.0001 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 0.0001
2nd Resistance Point 0.0001
1st Resistance Point 0.0001
Last Price 0.0001
1st Support Level 0.0001
2nd Support Level 0.0001
3rd Support Level 0.0001

See More

52-Week High 0.0300
Fibonacci 61.8% 0.0186
Fibonacci 50% 0.0150
Fibonacci 38.2% 0.0115
Last Price 0.0001
52-Week Low 0.0001

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar